focus -WSS

focus

author：hotspot 2025-09-30 19:25:15 - browse：523

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： An inside look at PIPEs, biotech's buzzy new financing tool

WSS

Why health records don't always know when patients are dead

David Ricks of Eli Lilly: best biopharma CEO of 2023

In Spain, a hospital brews its own CAR

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Can sheer will power keep patients alive in their dying hours?

International team creates first chimeric human

hotspot

focus

Wikipedia

New air purifier tech could be key to improving indoor air quality

ALS groups 'won't be played again' by the FDA, drug sponsors

Sports medicine is finally prioritizing gender equality

RSV vaccines may be linked to small increased risk of developing GBS

Drug repurposing or repositioning? The language matters

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Wildfire smoke exposes gaps in outdoor worker protections

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Medical records are filled with copy

How to address the problem of discarded donor organs

leisure time

How to address the problem of discarded donor organs

CRISPR gene editing developments we’re watching in 2024

Pfizer highlights cancer drugs it thinks could reignite investor interest

Obesity now affects over 1 billion people worldwide, study finds

RaDonda Vaught to speak at CommonSpirit event on patient safety

Change Healthcare cyberattack outage could last weeks

entertainment

Wikipedia

entertainment

knowledge